Efficacy and Safety of Trifluridine/Tipiracil Treatment in Patients With Metastatic Gastric Cancer Who Had Undergone Gastrectomy

Authors:

Abstract
Survival outcomes are poor for patients with metastatic gastric cancer or gastroesophageal junction cancer (mGC/GEJC), with a median survival time of 3 to 5 months without chemotherapy.1,2 Chemotherapy extends median overall survival (OS) by nearly 7 months,2,3 but ultimately the disease becomes refractory to chemotherapy, and all patients experience disease progression after first-line treatment.4-6 Duration of response to second-line treatment is short,4-6 and there are few options for third- and later-line therapy.

This publication has 41 references indexed in Scilit: